Avidity Biosciences, which trades under the NASDAQ ticker symbol RNA, was acquired by the major multinational pharmaceutical corporation Novartis in a massive strategic transaction valued at approximately twelve billion dollars. This high-profile acquisition integrated the biotechnology firm's advanced antibody-oligonucleotide conjugate pipeline into Novartis's global drug portfolio, expanding its therapeutic reach into innovative genetic and neuromuscular disease treatments.